CAR‐T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26583
Abstract: In this open‐label, single‐arm, phase I/II clinical trial, we evaluated the efficacy of anti‐B cell maturation antigen (BCMA) chimeric antigen receptor (CAR)‐T cell (HDS269B) therapy in 49 relapsed/refractory multiple myeloma (RRMM) patients, including 20 with… read more here.
Keywords: cell; therapy; car; maturation antigen ... See more keywords
Soluble B‐cell maturation antigen in multiple myeloma
Sign Up to like & getrecommendations! Published in 2024 at "American Journal of Hematology"
DOI: 10.1002/ajh.27225
Abstract: B‐cell maturation antigen (BCMA) has emerged as a promising immunotherapeutic target in multiple myeloma (MM) management, with the successive approval of antibody‐drug conjugates, bispecific antibodies, and chimeric antigen receptor T‐cell therapies directed to this membrane… read more here.
Keywords: cell maturation; multiple myeloma; antigen; maturation antigen ... See more keywords
B‐cell maturation antigen‐specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Cancer"
DOI: 10.1002/ijc.33002
Abstract: Despite major advances in the treatment of multiple myeloma (MM), it remains a largely incurable disease with long‐term control often dependent on continuous therapy. More effective, better tolerated treatments are therefore required to achieve durable… read more here.
Keywords: maturation antigen; multiple myeloma; antigen; cell maturation ... See more keywords
An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2021 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2021.1872540
Abstract: ABSTRACT Introduction: B-cell maturation antigen (BCMA) targeted therapy (BCMA-TT) has emerged as a promising treatment for Multiple Myeloma (MM). the three most common treatment modalities for targeting BCMA are antibody-drug conjugates (ADCs), bispecific antibody constructs,… read more here.
Keywords: maturation antigen; antibody; multiple myeloma; antigen ... See more keywords
Normalization of serum B‐cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.16752
Abstract: Serum B‐cell maturation antigen (sBCMA) is a novel biomarker for B‐cell malignancies. A normal reference range ( read more here.
Keywords: maturation antigen; serum cell; treatment; cell maturation ... See more keywords
Gene therapy with B‐cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18230
Abstract: The delivery of bispecific antibodies (BsAbs) targeting B‐cell maturation antigen (BCMA) and CD3 using the gene therapy approach is a promising alternative for BsAb administration in patients with multiple myeloma (MM). In the present study,… read more here.
Keywords: cell maturation; cd3; maturation antigen; gene therapy ... See more keywords
Abstract CT001: Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-ct001
Abstract: Background We report pivotal results from the registrational filing data cut-off (DCO) of the 200 mg dose used in the LINKER-MM1 (NCT03761108) clinical trial, testing the safety and efficacy of linvoseltamab (a B-cell maturation antigen… read more here.
Keywords: cell maturation; linvoseltamab; response; maturation antigen ... See more keywords
Role of B-Cell Maturation Antigen (BCMA) Targeted Immunotherapies in Relapsed and Refractory Multiple Myeloma- a Systematic Review
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-131849
Abstract: Introduction Multiple Myeloma (MM) is a plasma cell dyscrasia characterized by neoplastic proliferation of plasma cells. Despite the recent advances in disease management, it still contributes to significant morbidity and mortality, thus highlighting the unmet… read more here.
Keywords: maturation antigen; myeloma; bcma; multiple myeloma ... See more keywords
The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-203723
Abstract: BACKGROUND Elranatamab is a humanized bispecific antibody that targets both B-cell maturation antigen (BCMA)-expressing multiple myeloma (MM) cells and CD3-expressing T cells. Elranatamab is currently approved for the treatment of relapsed/refractory MM (RRMM) in the… read more here.
Keywords: cell maturation; bcma; baseline; maturation antigen ... See more keywords
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
Sign Up to like & getrecommendations! Published in 2018 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2018.01821
Abstract: The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM).… read more here.
Keywords: maturation antigen; bcma; multiple myeloma; antigen ... See more keywords